Case Report: Probable blinatumomab-associated lung injury in a pediatric patient with B-ALL
Year: 2026
Type: article
Study design: Case Report
Abstract: Blinatumomab is a bispecific T Cell engager targeting CD3 and CD19. Initially approved for relapsed/refractory B Cell acute lymphoblastic leukemia (B-ALL), it was later extended to first-line B-ALL therapy. Despite its high efficacy, blinatumomab carries risks of adverse effects, including cytokine release syndrome and neurotoxicity. Blinatumomab-associated lung injury is exceptionally rare. We report a pediatric B-ALL patient who developed drug-induced lung injury following induction chemotherapy, with recurrence of lung injury after blinatumomab administration. The patient presented with dyspnea, hypoxemia, and radiographic findings suggestive of interstitial lung injury. After excluding infectious and other non-infectious etiologies, we considered blinatumomab-associated lung injury as the most likely diagnosis. Symptoms improved markedly following corticosteroid therapy. Clinicians should be alert to blinatumomab-associated lung injury, achieve early recognition and administer glucocorticoid intervention. A dose-escalation strategy facilitates successful rechallenge.
Source: Frontiers in Pharmacology
Authors: Xingxing Feng, Tiantian Yin, Juan Han, Fen Zhou
Institution: Huazhong University of Science and Technology
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7223134103